Breo Ellipta Now Approved as Asthma Treatment for Adult Patients in Canada – Lung Disease News


Lung Disease News

Breo Ellipta Now Approved as Asthma Treatment for Adult Patients in Canada
Lung Disease News
GlaxoSmithKline (GSK) and VIBATIV® (telavancin) developer Theravance Biopharma, have just been granted Canadian approval for Breo Ellipta, a once-a-day maintenance treatment for asthma in patients who are at least 18 years old and have reversible …

and more »

View full post on asthma – Google News

Leave a Reply

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.